[{"Assets_0_Q2_USD":733997000.0,"CommonStockSharesConverted_0_Q2_shares":121631278.0,"CommonStockSharesOutstanding_0_Q2_shares":121631278.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-55148000.0,"NetIncomeLossConverted_1_Q2_USD":-41243000.0,"NetIncomeLossConverted_2_Q2_USD":-72829000.0,"StockholdersEquity_0_Q2_USD":655635000.0,"EarningsPerShareBasic_1_Q2_USD":-0.41,"EarningsPerShareBasic_2_Q2_USD":-0.74,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20190807"}]